Aviceda Therapeutics, Inc. of CAMBRIDGE, MA, a company, filed a Form D amendment with the SEC on 2025-01-13. The offering totals $207.5M, of which $75.0M was reported sold. Industry: Biotechnology.
Showing 25 of 26 people.
| Name | Role | Location |
|---|---|---|
| Christoph Adams | Director | Cambridge, MA |
| Mohamed Genead | Director | Cambridge, MA |
| David Guyer | Director | Mt. Arlington, NJ |
| Erin Lavelle | Director | Charlottesville, VA |
| Nancy Thomason | Director | Cambridge, MA |
| Michael Tolentino | Director | Cambridge, MA |
| Jay Woods | Director | Cambridge, MA |
| David Callanan | Executive Officer | Cambridge, MA |
| Mohamed Genead | Executive Officer | Cambridge, MA |
| Tarek Hassan | Executive Officer | Cambridge, MA |
| Derek Kunimoto | Executive Officer | Cambridge, MA |
| Michael Tolentino | Executive Officer | Cambridge, MA |
| Patrick Johnson | Director | Elgin, TX |
| Derek Kunimoto | Director | Cambridge, MA |
| Robert Kniaz | Director | Ivry-sur-Seine, I0 |
| Mariusz Gralewski | Director | Brookline, MA |
| Kyrylo Bigay | Director | Brookline, MA |
| Kyrylo Bigay | Executive Officer | Brookline, MA |
| Dmytro Voloshyn | Director | Brookline, MA |
| Paul Vukelic | Director | Cambridge, MA |
| Ross Darwin | Director | Brookline, MA |
| Derek A Kunimoto | Director | Cambridge, MA |
| Derek A Kunimoto | Executive Officer | Cambridge, MA |
| Michael A Tolentino | Director | Cambridge, MA |
| Mohamed A Genead | Director | Cambridge, MA |
| Filed | Form | Offering | Sold |
|---|---|---|---|
| 2024-11-22 | D | $200.0M | — |
| 2024-05-31 | D | $27.7M | $18.9M |
| 2023-05-19 | D | $15.6M | $15.6M |
| 2022-03-28 | D | $79.7M | $49.5M |
| 2022-03-28 | D | $26.2M | $8.4M |
| 2021-08-12 | D | $1.9M | $1.9M |
| 2020-09-16 | D | $4.3M | $4.3M |